{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T10:18:34Z","timestamp":1777025914617,"version":"3.51.4"},"reference-count":16,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1016\/j.clinthera.2008.10.013","type":"journal-article","created":{"date-parts":[[2008,11,18]],"date-time":"2008-11-18T11:26:59Z","timestamp":1227007619000},"page":"1817-1830","source":"Crossref","is-referenced-by-count":39,"title":["Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: A dose\u2014block-randomized, double-blind, placebo-controlled, ascending single-dose, phase I study"],"prefix":"10.1016","volume":"30","author":[{"given":"Kyoung Soo","family":"Lim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Ryul","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-Jung","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwang-Hee","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyu-Pyo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jang-Hee","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joo-Youn","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun-Suk","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung-Sang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Goo","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O Hwan","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dal-Mi","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong-Ae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In-Jin","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2008.10.013_bib1","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2008.10.013_bib2","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.2337\/db07-0697","article-title":"Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice","volume":"56","author":"Flock","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2008.10.013_bib3","doi-asserted-by":"crossref","first-page":"869","DOI":"10.2337\/diacare.25.5.869","article-title":"Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes","volume":"25","author":"Ahren","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2008.10.013_bib4","first-page":"512","article-title":"From the bench to the bedside: Dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents","volume":"11","author":"Pei","year":"2008","journal-title":"Curr Opin Drug Discov Devel"},{"key":"10.1016\/j.clinthera.2008.10.013_bib5","unstructured":"LG Life Sciences Ltd. (2007). Clinical Study Report. LGDPCL001. Seoul, Republic of Korea."},{"key":"10.1016\/j.clinthera.2008.10.013_bib6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1021\/jm0493156","article-title":"(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes","volume":"48","author":"Kim","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.clinthera.2008.10.013_bib7","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/jat\/31.6.321","article-title":"Toxicological screening in urine: Comparison of two automated HPLC screening systems, toxicological identification system (TOX.I.S.*) versus REMEDI-HS","volume":"31","author":"Sch\u00f6nberg","year":"2007","journal-title":"J Anal Toxicol"},{"key":"10.1016\/j.clinthera.2008.10.013_bib9","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.clpt.2005.09.002","article-title":"Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses","volume":"78","author":"Herman","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2008.10.013_bib10","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/sj.ki.5002011","article-title":"The effect of a shift in sodium intake on renal hemodynamics is determined by body mass index in healthy young men","volume":"71","author":"Krikken","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.clinthera.2008.10.013_bib11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.bbapap.2005.05.010","article-title":"Type 2 diabetestherapy with dipeptidyl peptidase IV inhibitors","volume":"1751","author":"Demuth","year":"2005","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.clinthera.2008.10.013_bib12","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.clinthera.2006.01.015","article-title":"Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A doubleblind, randomized, placebo-controlled study in healthy male volunteers","volume":"28","author":"Bergman","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2008.10.013_bib13","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1007\/BF00401846","article-title":"Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships","volume":"38","author":"Ritzel","year":"1995","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2008.10.013_bib14","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/sj.clpt.6100014","article-title":"Drug development and the FDA's Critical Path Initiative","volume":"81","author":"Woosley","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2008.10.013_bib15","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/sj.clpt.6100017","article-title":"Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs","volume":"81","author":"Wagner","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2008.10.013_bib16","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/sj.clpt.6100167","article-title":"Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: Focus on sitagliptin","volume":"81","author":"Herman","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2008.10.013_bib17","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1177\/0091270006289850","article-title":"Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects","volume":"46","author":"Herman","year":"2006","journal-title":"J Clin Pharmacol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291808003342?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291808003342?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,24]],"date-time":"2018-12-24T08:56:21Z","timestamp":1545641781000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291808003342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":16,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["S0149291808003342"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2008.10.013","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}